🕒 Last update: loading…21/11/2026

Stock UCB S.A. UCB.BR

UCB S.A. — Investlytic score 3/5 on the five criteria.

-
-
60/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 3/5 criteria met. Data as of 11/11/2026.

  • ✅ Price trend passed
  • ✅ Growth passed
  • ✅ Debt passed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): the price has been multiplied by at least 1.5.

Price change 2018 → 2019: -0.56%

Price change 2019 → 2020: 19.15%

Price change 2020 → 2021: 18.79%

Price change 2021 → 2022: -26.70%

Price change 2022 → 2023: 7.26%

Price change 2023 → 2024: 143.60%

Price change 2024 → 2025: 24.14%

Price change 2025 → 2026: 23.89%

Price change 2026 (year to date): 26.22%

Financial growth

Revenue CAGR (8 years): 7.61%

Earnings CAGR (8 years): 9.99%

Growth status: positive trend (>1%/yr) in revenue and earnings.

Debt

Debt-to-equity ratio: 0.21

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: 25.55

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 1.07% from the high over 6 months.

Insufficient correction (< 10.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, mechanical verdict of the method (hold, watch, sell: the same for all) and the detail of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
UCB S.A.25.70.21+6.0 %🔒
Bayer AG11.71.44+1.8 %–
Boston Scientific Corporation14.30.51+6.5 %–
Becton, Dickinson and Company16.80.76+6.5 %–
Cencora, Inc.20.96.19+9.6 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by UCB S.A. over the latest fiscal years.

Revenue
8.5 bn USD
fiscal year 2025
Net income
1.7 bn USD
fiscal year 2025
Net margin
20.1 %
fiscal year 2025
Average annual growth
+7.7 %
Revenue growth over 5 years
Average annual growth
+7.2 %
Revenue growth over 10 years
Market cap
62.3 bn USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
20205.9 bn807 m13.7 %n/a
20216.4 bn1.2 bn18.3 %+8.0 %
20226.1 bn461 m7.6 %-4.5 %
20235.8 bn378 m6.5 %-4.8 %
20246.8 bn1.2 bn17.3 %+17.1 %
20258.5 bn1.7 bn20.1 %+25.8 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by UCB S.A. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
average accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
5.00
safe zone (above 2.99)
Piotroski Score
6 / 9
4 to 6: average accounts
DCF Value
347.17 EUR
DCF above share price · share price 283.20 EUR, gap +22.6 %
Net Debt / EBITDA
1.14 x
moderate debt
Fiscal year20212022202320242025
Cash and investments1.4 bn1.1 bn923 m1.8 bn2.5 bn
Total Debt2.1 bn2.9 bn3.0 bn3.0 bn2.2 bn
Net Debt860 m2.0 bn2.2 bn1.5 bn-6.0 m
Equity8.4 bn9.1 bn9.0 bn10.0 bn10.9 bn
Total assets14.2 bn15.9 bn15.5 bn17.3 bn18.2 bn
Operating cash flow1.5 bn1.0 bn761 m1.2 bn2.2 bn
Investments (capex)493 m371 m238 m234 m449 m
Free cash-flow997 m674 m445 m920 m1.9 bn
Share buybacks60.0 m42.0 m40.0 m162 m121 m
Dividends paid240 m247 m252 m259 m264 m

Amounts in EUR, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)24.52 x
Price / book value4.62 x
Return on Equity (ROE)19.5 %
Return on Invested Capital (ROIC)14.1 %
Net margin25.7 %
Debt / equity0.31 x
Current ratio1.20 x
Interest coverage15.39 x
Free cash-flow yield2.8 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.

+

Valuation and competitors

UCB S.A. compared with its sector on the same exchange and with its main competitors.

Company P/E
25.7

Direct competitors

CompanyMarket cap (USD)P/ENet margin
UCB S.A.62.3 bn25.720.1 %
Amgen Inc. AMGN252 bn20.821.0 %
AbbVie Inc. ABBV521 bn28.96.9 %
Regeneron Pharmaceuticals, Inc. REGN98.8 bn20.931.4 %
Eli Lilly and Company LLY1,358 bn45.831.7 %
Incyte Corporation INCY24.7 bn16.325.0 %
Celltrion, Inc. 068270.KS36.5 bn32.724.8 %
Novartis AG NOVN.SW302 bn19.525.6 %
Vertex Pharmaceuticals Incorporated VRTX137 bn28.332.7 %

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering UCB S.A. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
2 analysts

Breakdown of ratings

strong buy 0buy 2hold 0sell 0strong sell 0

Price targets: published for companies listed in the United States only.

Analyst forecasts

Fiscal yearRevenueNet incomeExpected EPS (range)P/E on this EPSAnalysts
20268.9 bn2.4 bn12.70 (10.74 / 15.33)23.316
20279.9 bn2.8 bn14.71 (13.37 / 17.47)20.216
202811.0 bn3.3 bn17.48 (14.79 / 21.35)17.012

Amounts in EUR, the reporting currency.

Track record against expectations: reported EPS above consensus 9 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 21/11/2026. An analyst rating or target is not a guarantee.

+

Dividends and earnings

UCB S.A.: dividend history, last distributions, stock splits and earnings releases.

Frequency
annual
Last dividend
1.45 EUR
ex-dividend on 04/05/2026
Last 12 months
1.45 EUR
number of payments: 1
Yield
0.6 %
on the last known price
Years of increases
17
consecutive
Years of payments
26
uninterrupted
00.360.721.091.452007 : 0.900 EUR2008 : 0.920 EUR20082009 : 0.920 EUR2010 : 0.960 EUR20102011 : 0.980 EUR2012 : 1.00 EUR20122013 : 1.02 EUR2014 : 1.04 EUR20142015 : 1.06 EUR2016 : 1.10 EUR20162017 : 1.15 EUR2018 : 1.18 EUR20182019 : 1.21 EUR2020 : 1.24 EUR20202021 : 1.27 EUR2022 : 1.30 EUR20222023 : 1.33 EUR2024 : 1.36 EUR20242025 : 1.39 EUR2026 : 1.45 EUR2026

Annual dividend per share (EUR), adjusted for splits. Light bar: current year, incomplete. Red bar: lower than the previous year.

Latest ex-dividend dates

Ex-dividendAmountPayment
04/05/20261.45 EURn/a
25/04/20251.39 EUR29/04/2025
26/04/20241.36 EUR30/04/2024
28/04/20231.33 EUR03/05/2023
29/04/20221.30 EUR03/05/2022
30/04/20211.27 EUR04/05/2021
04/05/20201.24 EUR06/05/2020
26/04/20191.21 EUR30/04/2019

Earnings releases

DatePublished EPSExpected EPSSurprise
30/07/20266.775.03+34.6 %
26/02/20266.444.95+30.1 %
31/07/20253.593.36+6.8 %
27/02/20252.852.58+10.5 %
25/07/20242.061.74+18.4 %
25/04/20241.581.36+16.2 %

Stock splits

DateOperation
04/01/1999split: 100 shares for 1

Factual data: ex-dividend history and earnings calendar, as of 20/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in UCB S.A.

Free float
63.0 %
share of freely traded shares

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 14/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
likely
head office in the EU or EEA, listed on a European exchange
Listing exchange
Euronext Brussels
IPO: 04/01/2000
ISIN code
BE0003739530
Workforce
9,052
full-time employees
Chief executive
Jean-Christophe Tellier
Next earnings
25/02/2027

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about UCB S.A.

What is the UCB S.A. share price?

Latest recorded price: 296.50 EUR on 13/11/2026, for a market cap of 62.3 bn USD.

What is the revenue of UCB S.A.?

8.5 bn USD for fiscal year 2025, with net income of 1.7 bn USD (net margin 20.1 %).

Does UCB S.A. pay a dividend?

Yes. Latest dividend: 1.45 EUR per share, ex-dividend on 04/05/2026. Over 12 months: 1.45 EUR. Yield on the latest known price: 0.6 %.

When does UCB S.A. report its next earnings?

The next release is expected on 25/02/2027. EPS expected by analysts: 7.09.

What do analysts say about UCB S.A.?

Out of 2 analysts: 2 buy or strong buy, 0 hold, 0 sell or strong sell.

What is the P/E ratio of UCB S.A.?

Trailing 12-month P/E of 25.7.

Is UCB S.A. stock eligible for the French PEA?

Likely: the company is headquartered in the European Union or the European Economic Area (ISIN BE0003739530) and the stock is listed on a European exchange. The institution holding the PEA confirms eligibility.

How many employees does UCB S.A. have?

9,052 full-time employees according to the latest published profile.

Who runs UCB S.A.?

Jean-Christophe Tellier is the company's chief executive.

07

Similar stocks